Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome.
OBJECTIVE
To determine whether, in accordance with observations in mouse models, high concentrations of the lipoprotein lipase inhibitors apolipoprotein (Apo) CI and ApoCIII are associated with increased triglyceride concentrations and decreased fat mass in men with the metabolic syndrome.


METHODS
Plasma ApoCI, ApoCIII, and triglyceride concentrations were measured in the postabsorptive state in 98 men with the metabolic syndrome. Subcutaneous and visceral fat areas were measured by 3T-magnetic resonance imaging.


RESULTS
Triglyceride concentrations were 49% higher, and the average visceral fat area was 26% lower (both P < 0.001), in subjects with high ApoCI and ApoCIII compared with low ApoCI and ApoCIII. Subjects with either high ApoCI or ApoCIII had 16% (P < 0.05) and 18% (P < 0.01) decreased visceral fat area, respectively.


CONCLUSIONS
High concentrations of ApoCI and ApoCIII are associated with increased triglycerides and decreased visceral fat mass in men with the metabolic syndrome. These findings translate mouse studies into human pathophysiology.
van der Ham
Rachel L M
RL
Section of Vascular Medicine, Department of Endocrinology and Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. r.l.m.van_der_ham@lumc.nl.
Alizadeh Dehnavi
Reza
R
Berbée
Jimmy F P
JF
Putter
Hein
H
de Roos
Albert
A
Romijn
Johannes A
JA
Rensen
Patrick C N
PC
Tamsma
Jouke T
JT
D000273:Adipose Tissue / Q000473:pathology*; D000368:Aged; D053302:Apolipoprotein C-I / Q000097:blood*; D053305:Apolipoprotein C-III / Q000097:blood*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000473:pathology; D008875:Middle Aged; D018579:Patient Selection; D014280:Triglycerides / Q000097:blood*
D053302:Apolipoprotein C-I; D053305:Apolipoprotein C-III; D014280:Triglycerides